Revolution in Oncology: How Stem Cell Transplants are Changing the Game in Cancer Treatment
Welcome, dear reader! It’s a pleasure to have you here as we embark on an enlightening journey into the world of stem cell transplants in oncology. This article is designed for those who are keen to learn more about cancer treatment options or are simply intrigued by the latest advancements in medical science. Consider this […]
One Niche to Rule Them All: Stem Cell-Lymphatic Interactome in Regeneration and Cancer
Shiri Gur-Cohen, Ph.D., UC San Diego, explains how her lab studies how epithelial stem cells communicate with their vascular microenvironment to advance regeneration and combat metastatic diseases. Video Transcript: [MUSIC] I’m excited to share with you today the work that we’re doing in my laboratory to enhance regeneration and to fight cancer. In my laboratory, […]
Updated Invectys and CTMC announce FDA clearance of IND application for anti-HLA-G CAR-T cell therapy
HOUSTON, Texas, Dec. 20, 2022 (GLOBE NEWSWIRE) — Invectys, Inc. and CTMC, a joint venture between MD Anderson Cancer Center and National Resilience, Inc., today announced Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application for a Phase 1/2a clinical study of IVS-3001, Invectys’s lead engineered human leukocyte antigen A (HLA-G) targeting chimeric antigen […]
Angiocrine Bioscience Announces it has been awarded a $15M Grant from the California Institute for Regenerative Medicine for AB-205 Phase 3 Clinical Trial
SAN DIEGO, Dec. 19, 2022 /PRNewswire/ — Angiocrine Bioscience, Inc., a clinical-stage biopharmaceutical company today announced that the California Institute for Regeneration Medicine (CIRM) has approved investing $15M in the Phase 3 registration study AB-205-301 (E-CELERATE), a multi-center, randomized, double-blind, placebo-controlled study of AB-205 in adults with lymphoma undergoing high-dose chemotherapy (HDT) and autologous hematopoietic cell transplantation (AHCT). AB-205 […]
IN8bio Announces FDA Clearance to Initiate a Phase 2 Clinical Trial of INB-400 Gamma-Delta T Cells for Glioblastoma
NEW YORK, Dec. 08, 2022 (GLOBE NEWSWIRE) — IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced that it has received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) to initiate a Phase 2 clinical trial of a genetically modified […]
Grant Awarded to Develop Genetically Engineered Stem Cell Products to Fight Gastroesophageal Cancer
NEW YORK, Nov. 9, 2022 /PRNewswire/ — The DeGregorio Family Foundation with support from the Torrey Coast Foundation Gastro Esophageal Investigator Network Initiative (GEMINI) has awarded $250,000 to Saar Gill, MD, PhD, of the University of Pennsylvania, to improve immunotherapy in gastroesophageal cancer by using the tools of genetic engineering to modify human blood-forming stem cells to produce highly specialized cancer-eating cells called […]
CAR T-Cell Therapy: Ask Dr. Alaa Ali
Alaa Ali, MD, MSC, is a clinician, instructor, and investigator in clinical and translational research at MedStar Georgetown’s Stem Cell Transplant and Cellular Immunotherapy program. In the following video, Dr. Alaa Ali explains what CAR T-cell therapy is and how it works, what the process is for creating CAR T-cells to fight cancer, the success […]
The Journey of a Cancer-Fighting Stem Cell Therapy
Frontiers in Medicine 2022 gathered Stanford Medicine’s scientific and philanthropic communities in the historic Frost Amphitheater to explore a future of medicine that is both innovative and human-centered. A future that harnesses AI and big data to transform how we deliver care. A future where knowledge of human biology at a cellular, molecular, and genomic […]
Emulating the heart – Developing blood stem cells to treat cancer
Making stem cells from a patient’s adult cells – rather than human embryos – is one of the holy grails in modern medicine treatments. New research brings us two steps closer. *** All content on NationalStemCellTherapy.com is for informational purposes only. All medical questions and concerns should always be consulted with your licensed healthcare provider.
Aflac and Be The Match partner to help diversify the National Blood Stem Cell Donor Registry and improve health equity
COLUMBUS, Ga. and MINNEAPOLIS, Sept. 8, 2022 /PRNewswire/ — Highlighting its 27-year commitment to children and families facing childhood cancer and sickle cell disease (SCD), Aflac, the number one provider of supplemental health insurance in the U.S.1 and Be The Match®, operated by the National Marrow Donor Program, which has helped facilitate more than 111,000 […]